Down 33.7% in 4 Weeks, Here's Why You Should You Buy the Dip in Lyell Immunopharma (LYEL)Zacks Investment Research • 05/19/26
Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2026GlobeNewsWire • 05/06/26
Lyell Immunopharma, Inc. (LYEL) Presents at 25th Annual Needham Virtual Healthcare Conference TranscriptSeeking Alpha • 04/17/26
Lyell Immunopharma Announces Participation in 25th Annual Needham Virtual Healthcare ConferenceGlobeNewsWire • 04/07/26
Lyell Immunopharma Reports Q4 and Full Year 2025 Business and Financial ResultsGlobeNewsWire • 03/12/26
Lyell Immunopharma Announces Closing of Additional $50 Million Tranche of Equity Private Placement and Appointment of Smital Shah as Chief Financial and Business OfficerGlobeNewsWire • 03/09/26
Lyell Immunopharma, Inc. (LYEL) Presents at TD Cowen 46th Annual Health Care Conference TranscriptSeeking Alpha • 03/06/26
Lyell Immunopharma Announces Initiation of Patient Dosing in First-of-Its-Kind Phase 3 Head-To-Head CAR T-Cell Clinical Trial in Aggressive Large B-Cell LymphomaGlobeNewsWire • 02/12/26
4 Drug, Biotech Stocks Rising More Than 50% in 2025 With Room to GrowZacks Investment Research • 12/24/25
Lyell Immunopharma Presents New Clinical Data from Ongoing Trial of Ronde-Cel Showing High Rates of Durable Complete Responses in Patients with Large B-cell Lymphoma at the 67th ASH Annual Meeting and ExpositionGlobeNewsWire • 12/07/25
Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2025GlobeNewsWire • 11/12/25
Lyell Immunopharma Acquires Exclusive Global Rights to a Next-Generation CAR T-Cell Product Candidate in Clinical Development for Metastatic Colorectal CancerGlobeNewsWire • 11/10/25
Lyell Announces Two Oral Presentations from the Phase 1/2 Clinical Trial of Ronde-Cel for the Treatment of Aggressive Large B-Cell Lymphoma at the 67th ASH Annual Meeting and ExpositionGlobeNewsWire • 11/03/25
Lyell Immunopharma Announces the Initiation of a Phase 3 Head-to-Head CAR T-Cell Therapy Clinical Trial in Aggressive Large B-Cell Lymphoma and Formation of Expert Steering CommitteeGlobeNewsWire • 09/03/25
Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2025GlobeNewsWire • 08/12/25
Lyell: 'Hold' Rating Based On Phase 3 LYL314 LBCL Treatment Program AdvancementSeeking Alpha • 07/22/25
Lyell Immunopharma Announces Positive New Clinical Data Demonstrating High Rates of Durable Complete Responses from the Phase 1/2 Trial of LYL314 for the Treatment of Aggressive Large B-cell LymphomaGlobeNewsWire • 06/17/25